Market Newsdesk

Lauterach, March 16, 2021 (GLOBE NEWSWIRE) — The international transport and logistics company Gebrüder Weiss posted net sales of 1.77 billion euros in its 2020 financial year. This represents a year-over-year increase of 3.7 percent (2019: 1.71 billion euros). As such, the company continues to drive the growth it has been generating in previous years. “Key to our positive development was the fact that we remained flexible and fully operational during the Covid-19 crisis – at all of our locations worldwide. We retained our ability to provide the transport solutions our customers need, despite repeated lockdowns and global cargo space shortages. Our employees have performed outstanding work under difficult conditions,” says Wolfram Senger-Weiss, Chairman of the Management Board at Gebrüder Weiss.

 

Best of both worlds: Digital strategy proves its value
The company set a milestone in its ongoing digitalization when it launched the new customer portal myGW in 2020. The online platform offers fast, direct, and straightforward access to all Gebrüder Weiss services while providing real-time status information. “Our digital strategy ‘Best of Both Worlds’ – by which we mean the combination of physical and digital competence – has proven itself successful during this crisis. We have been able to underscore our reputation as a reliable and innovative logistics partner. The positive customer feedback has reaffirmed our strategic direction,” says Wolfram Senger-Weiss. The customer portal is currently operating in Austria, Germany, Switzerland, Hungary, Slovakia, and the Czech Republic. A rollout into further countries is planned for this year.

 

Worldwide network expanded
The year 2020 also saw Gebrüder Weiss make renewed progress in strategically extending its global reach: in the air and sea freight division, Gebrüder Weiss added locations in Germany and entered the markets in Poland, South Korea, Malaysia, Australia, and New Zealand. “Given the restrictions on travel, the expansions were all implemented remotely. This involved daunting challenges for the various teams – which they managed well using digital communication tools,” says Senger-Weiss. The international network now comprises a workforce of 7,400 employees (full-time equivalent) at 170 locations in 35 countries. All in all, the logistics company invested more than 70 million euros in expanding and extending its terminal network and in IT infrastructure, as well as in acquisitions. The equity ratio again exceeded 60 percent, a major reason behind the company’s strength and ability to continue evolving despite adverse conditions.

 

In the United States, despite a very difficult environment in 2020, Gebrüder Weiss was able to move forward with plans to open a new warehouse in California’s Inland Empire. The US team navigated challenges to achieve an overall result that was better than expected.  “One of the reasons I believe we were able to overcome many of the obstacles we faced last year was because we prioritized the health and safety of our staff. This important effort helped ensure our customers’ supply chains experienced as little disruption as possible,” said Mark McCullough, CEO of Gebrüder Weiss USA.

 

Focus on sustainability: CO₂ neutrality by 2030
Clearly defined goals are also a hallmark of the Gebrüder Weiss sustainability strategy: with CO₂ emissions set to be reduced by ten percent annually, the company aims to be CO₂ neutral by 2030. The measures taken include the installation of further photovoltaic systems at its own logistics terminals, coupled with increasing the use of alternative drive technologies such as electricity, gas, and hydrogen for trucks. Since last year, Gebrüder Weiss has also been offering customers the option of offsetting their carbon emissions with support for certified climate protection projects.

 

The diverging development at the company’s individual divisions reflects the economic volatility of the past year. Given the various restrictions and the closures of some customers’ plants, especially during Q2, the land transport and logistics division saw its sales decline by 4.3 percent to 1.10 billion euros (2019: 1.15 billion euros). Higher demand in online retailing produced a 29 percent increase in home delivery consignments (1.37 million consignments in 2020) – an area in which Gebrüder Weiss is the market leader in Austria and several Eastern European countries. At 470 million euros, sales in air and sea freight were up by 23.7 percent (2019: 380 million euros). Along with a strong business performance, most notably in the air freight sector, the acquisition of Ipsen Logistics had a positive impact. Against a backdrop of severe challenges, DPD Austria, which is partly owned by the Gebrüder Weiss parcel service, delivered more than 57 million parcels. This increase of more than ten percent was successfully managed despite the coronavirus crisis.

 

About Gebrüder Weiss
Gebrüder Weiss, a global freight forwarder with a core business of overland transport, air, and sea freight and logistics, is the world’s oldest transport company with a history that dates back more than 500 years. The family-owned company employs more than 7,400 people worldwide and boasts 170 company-owned locations. The business established a presence in the United States in Chicago in 2017 and has since expanded its North American locations to include Atlanta, Boston, Dallas, Los Angeles, New York, San Francisco, Montreal, Toronto, and Vancouver. Developing and changing with its customers’ needs during its long history, Gebrüder Weiss is also a pioneer in sustainable business practices having implemented myriad ecological, economic, and social initiatives.  The company’s voyage into North America, along with its continuous growth, illustrates the need for highly experienced providers of global solutions through an international network of supply chain experts. Customized solutions with a single point of contact provide customers with an exceptional service experience focused on reliable and economical solutions.

 

Media Contact:

Karolyn Raphael, Winger Marketing

[email protected]

T  312-494-0422

 

Gebrüder Weiss

251 Wille Road, Suite C
IL 60018 Des Plaines

T 847.795.4300

[email protected]

www.gw-world.com

 

Contact

Gebrüder Weiss Corporate Communications

Merlin Herrmann

[email protected]

Bundesstrasse 110, A-6923 Lauterach

T +43.5574.696.2169

F +43.5.9006.2173

www.gw-world.com 

www.gw-world.com/de/news

 

Attachments

• Gebrueder_Weiss_Geschaeftsleitung
• Gebrueder_Weiss_Head_Office

Karolyn Raphael
Gebrüder Weiss
3124940422
[email protected]

SAN FRANCISCO and SUZHOU, China, March 16, 2021 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced the first patients have been dosed in its global Phase 1 clinical trial of ADG126 for the treatment of various advanced solid tumors. ADG126 is a fully-human, antagonistic monoclonal antibody (mAb) targeting a novel epitope of CTLA-4 and is Adagene’s lead SAFEbody™ product candidate.

“Dosing the first patients in our Phase 1 clinical trial of ADG126 is an exciting milestone for the development of our SAFEbody technology platform,” said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene. “SAFEbody technology is designed to mask antibody binding sites, which will be activated specifically within the tumor microenvironment (TME), to provide favorable safety and efficacy with significantly enhanced therapeutic windows. Our most advanced SAFEbody candidate, ADG126 targets a conserved epitope of CTLA-4 with broad species cross-reactivity for potent Treg depletion via strong antibody-dependent cellular cytotoxicity (ADCC) in TME versus peripheral tissue. Our preclinical studies provide proof-of-concept for the potential of ADG126 in leveraging our SAFEbody platform to overcome standing issues associated with existing anti-CTLA-4 therapies by limiting on-target off-tumor toxicities in normal tissues.”

“Existing cancer therapies that target CTLA-4 are associated with safety concerns, creating an unmet need for new anti-CTLA-4 therapies that are both safe and potent,” said Anthony W. Tolcher, M.D., FRCPC, FACP, medical oncologist, co-founder of NEXT Oncology ™, Adagene advisor and study investigator. “ADG126 demonstrated an impressive safety margin while maintaining its potent antitumor efficacy in pre-clinical studies, and I look forward to its evaluation in patients with advanced solid tumors.”

The global Phase 1 open-label, dose-escalation clinical trial is investigating the tolerability and anti-tumor activity of ADG126 in patients with advanced/metastatic tumors in multiple clinical sites in Australia. Adagene has also received approval from the FDA to initiate the Phase 1 clinical trial of ADG126 in the United States. The dose escalation trial will test five doses at 0.1, 0.3, 1.0, 3.0 and 10 mg/kg, with dose-limiting toxicities (DLT) evaluation for 3 weeks. Additional information about this clinical trial is available at ClinicalTrials.gov using the identifier: NCT04645069.

About ADG126

ADG126 is a fully human antagonistic mAb targeting a novel epitope of CTLA-4 and has been shown to specifically deplete regulatory T-cells in tumors. ADG126 is Adagene’s lead SAFEbody™ product candidate. The SAFEbody technology, developed using Adagene’s AI-powered platform, enables binding of an antibody to a specific target only after conditional activation of the antibody in target tissues.

In preclinical studies, ADG126 was well tolerated in cynomolgus monkeys in a four-week repeat-dose GLP toxicology study at doses up to 200 mg/kg, and demonstrated an encouraging antitumor response in multiple immune-competent mouse tumor models in a dose-dependent manner both as a single agent and in combination with anti-PD1 and other therapies.

Unlike anti-PD1/PD-L1 check point inhibitors, anti-CTLA-4 is known for its dose-dependent clinical response in single and combination therapies, which is severely limited by the narrow therapeutic window available to current anti-CTLA-4 therapies.  The large safety margin shown by ADG126 GLP toxicology studies of up to 200 mg/kg in targeting CTLA-4 will make it possible to dose patients for their optimal clinical benefits in single and combination therapies.

About Adagene

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary DPL platform, composed of NEObody, SAFEbody, and POWERbody technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: https://investor.adagene.com.

Safe Harbor Statement

This press release contains forward-looking statements, including statements regarding data from the ADG126 preclinical studies and Phase I clinical trial, the potential implications of clinical data for patients, and Adagene’s advancement of, and anticipated clinical development, regulatory milestones and commercialization of ADG126. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Investors Contact

Raymond Tam
Adagene
86-512-8777-3626
[email protected]

Bruce Mackle
LifeSci Advisors
646-889-1200
[email protected]

Media Contact

Annie Starr
6 Degrees
973-768-2170
[email protected]

VANCOUVER, B.C. / BOSTON, March 16, 2021 (GLOBE NEWSWIRE) — via InvestorWire – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging (“Lighthouse”).

Prior to Imagin’s selection of Lighthouse as its contract manufacturer for the i/Blue Imaging System™ in October 2020, the Company received multiple fully functional feasibility units from its original design partner, Optel, Inc. Lighthouse’s development program has since focused on further refining the design to support Imagin’s submissions to the U.S. Food and Drug Administration and to ensure final device performance, compliance with all applicable regulatory standards, and optimal manufacturability to meet both cost targets and anticipated user demand.

“We chose Lighthouse because of its accomplished history of taking innovative products like our i/Blue System and applying its cross-functional expertise in optics, electronics, software and mechanical design to move into commercial manufacturing,” commented Mike Vergano, Imagin’s Director of Engineering and Quality. “We have not been disappointed. The Lighthouse team’s work to-date has been exceptional, and we look forward to that continuing.”

“As previously reported, the impact of the COVID-19 pandemic in 2020 altered our product timeline by approximately nine months, moving expected completion into 2022,” said Jim Hutchens, Imagin’s President and CEO. “The good news is that Lighthouse’s program has stayed on schedule and we expect it to remain on target going forward.”

About Imagin Medical

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The Company believes its first product, the i/Blue™ Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The Company’s initial focus is bladder cancer. Learn more at www.imaginmedical.com.

Forward-Looking Statements


Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward- looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected.  Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

Contact:

Jim Hutchens
President & CEO
Telephone: 833-246-2446

Corporate Communications:

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Reported top-line results from Phase 2 SIGNAL study that indicates potential cognitive benefit of pepinemab in neurodegenerative disease. New Alzheimer’s study expected to begin enrollment in Q2

Phase 1/2 study to evaluate pepinemab in combination with KEYTRUDA® in advanced, recurrent or metastatic head and neck squamous cell carcinoma also expected to initiate enrollment in Q2

In first quarter 2021, raised $32 million in net proceeds through its pre-existing open sale market agreement

ROCHESTER, N.Y., March 16, 2021 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.

“We had a productive fourth quarter, during which we presented topline data from our SIGNAL phase 2 study in Huntington’s disease which indicated that treatment with pepinemab has a potential cognitive benefit in patients with Huntington’s disease,” stated Maurice Zauderer, Ph.D., president and chief executive officer. “Looking forward, during the second quarter of 2021 we anticipate initiating studies of pepinemab in head and neck cancer in combination with Merck’s KEYTRUDA® as well as a new trial in Alzheimer’s disease, with financial assistance from the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation. Importantly, having raised $32 million in the first quarter of 2021 through our open sale market agreement with Jefferies, we believe we are well positioned to fund these trials, which are anticipated for completion in H2 2022/Q1 2023. Based on existing clinical data, we are hopeful that the results will demonstrate the broad clinical potential of SEMA4D inhibition and support further development of pepinemab in these important indications.”

“With regards to our Huntington’s disease program, after completing analysis of the full data set, we believe there is a promising path forward in mid-stage disease, and we are currently engaged in potential partnering discussions to fund and execute a rigorously designed Phase 3 study,” Dr. Zauderer concluded.     

Pepinemab Clinical Updates:

• Alzheimer’s disease. Vaccinex previously announced that it had been awarded a $750,000 development grant from the Alzheimer’s Association under the 2020 Part the Cloud Program, as well as a $3 million award from the Alzheimer’s Drug Discovery Foundation. The awards were based in part on earlier findings that treatment with pepinemab prevented the characteristic loss of glucose transport in the brain during underlying Huntington’s disease progression as detected by conventional FDG-PET imaging. Uptake of glucose, the main source of energy in the brain, is also known to decline with underlying disease progression in Alzheimer’s disease. In particular, previous studies in AD have shown that decline in brain glucose transport correlates with cognitive decline and, more recently, that FDG-PET is a superior indicator of cognitive performance compared to Aβ amyloid-PET in AD.

Dr. Eric Siemers, MD, formerly senior medical director of the Alzheimer’s Disease Global Development Program at Eli Lilly and Company, will serve as Senior Medical Director of this randomized, placebo-controlled, multi-center clinical study which is expected to begin enrolling patients in 2Q 2021.

• Head and Neck cancer. In September 2020, Vaccinex announced a clinical collaboration with Merck to evaluate pepinemab in combination with Merck’s anti-PD-1 cancer immunotherapy, KEYTRUDA® (pembrolizumab), in a Phase 2 study for front-line treatment of advanced, recurrent or metastatic head and neck squamous cell carcinoma. Multiple prior studies suggest that inhibition of SEMA4D increases immune infiltration and alters the balance of cytotoxic and immunosuppressive cells in the tumor microenvironment. As SEMA4D is highly expressed in head and neck cancer, we believe there is strong rationale for development in this indication.

The Company expects to begin enrollment of up to 65 patients in the second quarter of 2021. The study is designed to assess whether combination therapy can significantly improve responses to KEYTRUDA® in this population. Key endpoints of the study are expected to include objective response, progression free survival and overall survival.

• Huntington’s disease. In September 2020, Vaccinex reported topline data from its Phase 2, double-blind, placebo-controlled SIGNAL trial of pepinemab in patients with early manifest and prodromal Huntington’s disease (HD). The study had two co-primary endpoints, a family of two cognitive assessments from the Huntington’s Disease Cognitive Assessment Battery and Clinical Global Impression of Change (CGIC).

Although the study did not meet the above pre-specified co-primary endpoints, we believe the results of each of the two cognitive assessments in patients with early manifest disease demonstrated a strong trend for beneficial change (OTS, p=0.028 and PTAP, p=0.06, 1-sided). Given the favorable trend of results, an exploratory endpoint, the HD-CAB composite score encompassing the full set of 6 different cognitive assessments was also evaluated and is believed to indicate highly significant treatment-related benefit (p=0.007). Similarly, the treating physicians’ evaluation of CGIC in these patients did not show a statistically significant difference between the placebo and pepinemab-treated groups. However, given the difficulty of detecting changes in CGIC at the top of the functional capacity scale (TFC 12-13), a subpopulation analysis of patients who were somewhat more advanced in disease progression at baseline (TFC 11) indicated an improved outcome (p=0.04, 1-sided), albeit in a smaller population that was not powered for statistical significance. Beneficial effects of pepinemab treatment were supported by imaging analysis. Exploratory volumetric MRI analysis of brain in patients with early manifest disease demonstrated statistically significant treatment-related reduction in atrophy of the brain caudate, a key brain region in early HD progression. In addition, FDG-PET analysis of metabolic activity indicated that treatment resulted in a statistically significant increase in glucose transport in the majority of brain regions examined.

Overall, we believe that the results of the SIGNAL trial suggest that pepinemab may help protect against cognitive decline during HD progression. Vaccinex is actively exploring partnering pepinemab for a large pivotal Phase 3 HD trial in collaboration with a biopharmaceutical partner.

• Other Trials. Pepinemab is also being evaluated in multiple investigator-sponsored trials (ISTs) being conducted by the Winship Cancer Institute of Emory University to evaluate pepinemab in combination with checkpoint inhibitors in “Window of Opportunity” studies in colorectal, pancreatic, head and neck cancer and melanoma.

Other Recent Accomplishments:

• Entered into multi-project deals with two leading pharmaceutical companies focused on leveraging Vaccinex’s ActivMAb® antibody discovery and novel viral display platform to discover drugs against complex membrane receptors such as GPCRs and ion channels.
• Announced that Surface Oncology will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex’s ActivMAb® platform. The terms of agreement with Surface Oncology provided that Surface Oncology pay technology access and licensing fees in addition to research funding, and that Vaccinex will qualify for development milestone payments and royalties on commercial sales.
• Subsequent to the end of the fourth quarter, the Company raised $32 million in net proceeds through its existing open sale market agreement, or ATM.

Upcoming Anticipated Milestones:

• Q2 2021 – Planned initiation of a Phase 1b/2 clinical trial of pepinemab in combination with KEYTRUDA® for the treatment of patients with HNSCC
• Q2 2021 – Expected initiation of Alzheimer’s disease Phase 1/2 trial
• H2 2022 – Data anticipated from open head and neck cancer trial of combination immunotherapy with KEYTRUDA®
• Late 2022/Q1 2023 – Data anticipated from randomized Alzheimer’s trial

Financial Results for the Three and Twelve Months Ended December 31, 2020:

Revenue. Revenue for the year ended December 31, 2020 was $625,000 as compared to $523,000 for the year ended December 31, 2019. The Company’s revenues were generated primarily from a grant awarded under the Part the Cloud Program from the Alzheimer’s Association.

Research and Development Expenses. Research and development expenses for the three months ended December 31, 2020 were $4.2 million as compared to $4.4 million for the comparable period in 2019. For the full year 2020, research and development expenses were $21.5 million as compared to $25.7 million for the full year 2019. Research and development expense decreased compared to the prior year periods primarily as a result of decreased spend associated with the Huntington Disease trial.

General and Administrative Expenses. General and administrative expenses for the three months ended December 31, 2020 were $1.8 million as compared to $1.9 million for the comparable period in 2019. For the full year 2020, general and administrative expenses were $7.4 million as compared to $6.7 million for the full year 2019. The increased expense versus the prior year was primarily driven by increased D&O insurance premiums.

Cash and Cash Equivalents and Marketable Securities. Cash and cash equivalents and marketable securities on December 31, 2020 were $10.6 million, as compared to $2.8 million as of December 31, 2019. Subsequent to the end of the fourth quarter 2020, the Company raised $32 million in net proceeds through its pre-existing ATM.

About Vaccinex, Inc.

Vaccinex, Inc. is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers chronic inflammation in the brain. The Company additionally intends to leverage its proprietary drug discovery platform, ActivMAb^®, to create opportunities for future pipeline expansion and strategic collaborations, particularly by exploiting its unique capability to select high value antibodies against important multi-pass membrane receptors including GPCR and ion channels.

Forward Looking Statements

To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Such statements include, but are not limited to, statements about our plans, expectations and objectives with respect to the results and timing of our clinical trials of pepinemab in various indications, the use and potential benefits of pepinemab in Huntington’s and Alzheimer’s disease and other indications, and other statements identified by words such as “may,” “will,” “appears,” “expect,” “exploratory,” “planned,” “anticipate,” “estimate,” “intend,” “hypothesis,” “promising,” “potential,” “hopeful,” “advance,” and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of our research and pre-clinical development programs, clinical development programs, future results, performance, our history of operating losses and need to raise additional capital to continue as a going concern, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab, the impact of the COVID-19 pandemic, and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Securities and Exchange Commission (“SEC”) and the other risks and uncertainties described in our Form 10-K dated March 9, 2020 and subsequent filings with the SEC.

Investor Contact  Jeremy Feffer  LifeSci Advisors, LLC  212-915-2568  [email protected]

Media Contact Cait Williamson, Ph.D. LifeSci Communications, LLC 646-751-4366 [email protected]